Proving the Business Case for the Internet of Things

Parexel sensor aims to transform clinical trials

Steve Rogerson
April 11, 2017
A sensor from Massachusetts-based Parexel can gather data securely from patients in clinical trials
The patient sensor securely captures, transmits, stores and visualises study subject data in clinical trials. It is powered by the Perceptive MyTrials analytics platform, enabling an end-to-end services and technology that facilitates the remote collection of study subject data via medical devices.
Collection of clinical data via wearables and sensors could replace or reduce the number of clinical assessments and/or on-site visits during clinical trials. This could potentially reduce the burden on trial participants and sites as well as decrease trial costs.
Wearable monitoring also allows data to be collected more often. Frequent collection of these data can provide real-time meaningful insights into a study subject’s behaviour and health outside of visits, supporting better compliance and real-time user feedback.
Parexel’s clinical trial expertise and the ability to collect sensor-based data is designed to create efficiencies, eliminating the need to contract separately for wearable third-party devices to leverage sensors in a clinical study. According to Frost and Sullivan, the global market for wearables in healthcare is expected to reach $18.9bn in 2020.
“Due to evolving regulatory and payer standards in today’s healthcare market, there is a growing need to leverage alternative data sources in clinical trials,” said Xavier Flinois, president of Parexel Informatics. “Wearables and sensors have the potential to transform phase I to IV trials as well as observational studies. However, infrastructure and multi-functional expertise are needed to validate the appropriate use of medical devices to generate clinical and quality-of-life endpoints.”
He said that Parexel’s offering could disrupt the industry standard of collecting data during site visits only, allowing biopharmaceutical sponsors to demonstrate safety and/or efficacy and differentiate treatments from competition using remote monitoring approaches.
The patient sensor supports the generation of real-world data that can demonstrate value beyond the data collected during site visits. To deliver this, the company has partnered with technology providers, including OSIsoft, to capture, securely transmit, store and monitor data, as well as generate alerts based on the potentially large volume of time-series data from sensors.
Headquartered near Boston, Massachusetts, Parexel has offices in 85 locations in 51 countries around the world, and has approximately 19,625 employees.